Long Shortz with Recce: $15 million capital raise for Phase 3 Indonesian and Australia trials
Recce Pharmaceuticals raises $15.8 million to advance its Phase 3 trials for its topical gel treatment in Indonesia and Australia.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Tylah Tully chats with Recce Pharmaceuticals (ASX:RCE) managing director and CEO James Graham about the company's recent placement.
Recce's raised $7.4 million in an entitlement offer shortfall, the final part of a broader $15.8 million capital raising effort.
Funds raised will be used to support Recce's Phase 3 clinical trials for topical treatments in Indonesia and Australia, which will progress the company through to commercialisation, and an Investigational New Drug Application to the US FDA.
Watch the video to learn more about the company.
This video was developed in collaboration with Recce Pharmaceuticals, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
Originally published as Long Shortz with Recce: $15 million capital raise for Phase 3 Indonesian and Australia trials
Astral strikes more gold at Feysville
A 17-hole campaign at Kamperman in the Feysville project focused on infill drilling and tested multiple structural orientations, aiming to unlock the high-grade gold potential.
Read more
Dispelling private credit myths
As the once ‘alternative’ asset that is private credit becomes a portfolio staple, distinguishing risk from opportunity – and fact from fiction – remains a key challenge.
Read more